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Implication for health policy/practice/research/medical education:
In an experimental study, we found, atorvastatin with a dose of  150 mg/kg/day for 7 days was nephrotoxic for rats, while 
lower doses at 10 mg/kg/day or 50 mg/kg/day for 7 days were not accompanied by renal injury. These findings imply further 
attention to the administration of  higher doses of  atorvastatin in clinical conditions.  
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1. Background
Since the discovery of  3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase inhibitors 
(statins) in 1976, they have been described as the 
principal and the most effective agents for reducing 
serum cholesterol values (1,2). Statins have proven 
their beneficial effects in reducing total and LDL-
cholesterol as well as triglycerides, and in increasing 
HDL-cholesterol (2). Statins are amongst the most 
widely recommended drugs, with established benefits 
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Background: Recent retrospective observational studies suggest that high-potency statin 
therapy might increase the risk of acute kidney injury, however data on this subject is scares. 
Objectives: This study, was designed to investigate the renal tubular cell effect of different 
doses of atorvastatin to detect the possible aggravation of renal function or morphology 
of the kidney.
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equal groups and treated as follows. Control group received phosphate buffer as the vehicle 
of atorvastatin for 7 days. Groups 1, II and III received atorvastatin at doses of 10, 50 and 
150 mg/kg daily for 7 days, then on the day 8, all rats were anesthetized using ketamine and 
the blood samples were collected for evaluation of creatinine (Cr) and blood urea nitrogen 
(BUN) levels and then all rats were sacrificed, then the animals’ kidneys were dissected out 
and histopathological studies were performed 
Results: Mean (±SD) of scores of injury to renal tubular cells in control group was 4.2 
±2.2 and in groups I, II and III were 6.44 ± 4.9, 15.4± 8.5 and 25.8 ± 12.7 respectively. 
Group III which received 150 mg/kg/day of atorvastatin had significant renal damage in 
comparison to control group (P < 0.001). There was no significant difference of renal injury 
score between control group with groups of I and II. 
Conclusions: In the present study we found, atorvastatin with a dose of 150 mg/kg/day for 
7 days was nephrotoxic for rats, while lower doses at 10 mg/kg/day or 50 mg/kg/day for 7 
days were not accompanied by renal injury. These findings imply further attention to the 
administration of higher doses of atorvastatin in clinical conditions.
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in patients at risk of  heart disease. Statins have had 
a dramatic impact on the primary and secondary 
prevention of  cardiovascular disease. However, 
the efficiency and relative safety of  HMG-CoA 
(3-hydroxy-3-methylglutaryl coenzyme A) reductase 
inhibitors, has permitted many to argue for universal 
statin administration in everyone older than 50 years 
(3,4). While, administration of  high-potency statins 
has been detected to be more efficient in improving 
cardiovascular outcomes than use of  lower-potency 
statins, but, recent concerns about the risks of 
rhabdomyolysis and acute kidney injury, diabetes 
mellitus, and memory impairment have prompted 
some investigators to detect more precisely the side 
effects of  statins (5). Indeed, a few retrospective 
observational studies suggest that high-potency statin 
therapy might increase the risk of  acute kidney injury, 
however data on this subject is scares (6).
2. Objectives
This study therefore, was designed to investigate 
the renal tubular cell effect of  different doses of 
atorvastatin to detect the possible aggravation of 
renal function or morphology of  the kidney.
3. Materials and Methods
3.1. Animals
In this experimental study 30 male Wistar rats 
weighing 200-250 g were selected and similarly 
handled in the animal house of  Isfahan University 
of  Medical Sciences, Isfahan, Iran. The animals were 
kept at a controlled environment with 50%-60% 
humidity and temperature of  25 ± 3°C. Additionally, 
the rats were housed with a 12 hours dark-light cycle 
(lights on at 7:00 am) and permitted free access to 
pelleted diet and tap water. They were also housed in 
animal lab at least one week prior to the experiment. 
During the investigation, the animal’s general health 
state and activity were monitored closely. The project 
was confirmed by the Ethical Committee of  Isfahan 
University of  Medical Sciences, Isfahan, Iran and 
all animal experimentations were performed in 
accordance with the National Institute of  Health 
guidelines for the careful use of  laboratory animals. 
3.2. Drugs and chemicals 
Atorvastatin was prepared from Kharazmi 
Pharmaceutical Company (Tehran, Iran), and 
administered intraperitoneally (i.p.). 
3.3. Experimental design 
In this experimental study 24 male Wistar rats were 
designated into 4 equal groups and treated as follows. 
Control group received phosphate buffer as the 
vehicle of  atorvastatin for 7 days. Groups 1, II and 
III received atorvastatin at doses of  10, 50 and 150 
mg/kg daily for 7 days, then on the day 8, all rats were 
anesthetized using ketamine and the blood samples 
were collected for evaluation of  creatinine (Cr) and 
blood urea nitrogen (BUN) levels and then all rats 
were sacrificed.
3.4. Histopathological examination
At the end of  the experiment the animals’ kidneys 
were dissected out and fixed in buffered formalin 
for 12 hours and processed for histopathological 
examinations. Three μm-thick paraffin sections were 
stained with Hematoxylin and Eosin (H&E) for 
light microscopic examination using conventional 
protocol.
Histopathological studies were performed under a 
light microscope. Slides were coded and examined 
by a nephropathologist who was blinded to the 
treatment groups. All specimens were examined for 
morphologic parameters including epithelial cell 
degeneration, vacuolization, tubular dilatation, tubular 
cell flattening and presence of  hyaline cast and debris 
materials in tubular lumen.
3.5. Statistical analysis
All Numerical variables with a normal distribution 
were expressed as mean ± SD and categorical 
variables are presented as percentage. According to 
normal data distribution, one-way analysis of  variance 
(ANOVA) and post hoc tests (Bonferroni test) were 
used for the comparison of  mean values between 
groups. A new variable of  score was generated by 
means of  histopathology evaluations of  degeneration, 
vacuolization, tubular dilatation, tubular cell flattening 
and presence of  hyaline cast and debris of  injury to 
renal tubular cells. P values of  less than 0.01 were 
assumed to be significant (P < 0.01). Data analysis was 
done using Stata software (Release 12, Stata Corp., 
College Station, TX). 
4. Results
Mean (±SD) of  scores of  injury to renal tubular 
cells in control group was 4.2 ± 2.2 and in groups I, 
II and III were 6.44 ± 4.9, 15.4 ± 8.5 and 25.8 ± 12.7 
respectively. Mean (±SD) of  scores of  injury to renal 
tubular cells was illustrated in Table 1. Group III 
which receive 150 mg/kg/day of  atorvastatin had 
significant renal damage in comparison to control 
(buffer) group (P < 0.001). There was no significant 
difference of  renal injury score between control 
group with groups of  I and II. Comparison between 
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groups was summarized in Tables 2 and 3.
5. Discussion
In the present study we found, atorvastatin with a 
doses of  150 mg/kg/day for 7 days was nephrotoxic 
for rats. While lower doses at 10 mg/kg/day or 50 
mg/kg/day for 7 days was not accompanied by renal 
injury.
Inflammation is highly prevalent in patients with 
chronic renal failure and is consistently associated 
with cardiovascular mortality and morbidity (7). 
Dyslipidemia are encountered as the major risk factor 
for atherosclerosis and its associated conditions like 
coronary artery disease, peripheral vascular disease 
and ischemic cerebrovascular disease (7). One of  the 
drugs that are available to treat dyslipidemias consist 
the statins (3-hydroxy-3-methylglutaryl coenzyme A 
reductase inhibitors). While a bulk of  clinical evidences 
has demonstrated that statin therapy significantly 
reduces the risk of  new or recurrent cardiovascular 
events and stroke, and ameliorates survival of 
individuals with previous cardiovascular disease (1-3), 
however, clinical trials of  transplant survival reveal the 
therapeutic potential of  statins as immunosuppressive 
agents. Statins protect against rejection of  cardiac 
transplantations and may be beneficial in pulmonary 
and kidney transplantation. Interestingly, some 
investigations support the protective role of  statins 
in heart graft survival. The beneficial properties of 
statins implies modification of  endothelial function, 
plaque stability, and, specially, inflammatory pathways. 
These properties are addressed to as ‘pleiotropic 
effects’ of  statins. Existence of  these pleiotropic 
actions reveals that statins might be beneficial in 
the treatment of  patients with chronic renal failure. 
In addition, statins are able to act in the kidney as 
a potent free radical scavenger and inhibit mitogen 
activated protein kinase and nuclear factor kappa B. 
Statins also are capable to inhibit signaling pathways 
activation by reactive oxygen species and therefor 
prevents tubular cell apoptosis induced by various 
nephrotoxins (4,5). Additionally statins affect, various 
signaling pathways involving renal inflammatory, 
proliferative, and cell-death responses. Hence, 
statins exert anti-inflammatory actions in renal 
tissue (6). Moreover, renal antioxidant efficacies with 
subsequent endothelial function regulation of  renal 
vasculature, after statin administration, may also 
explain the pleiotropic protection against renal injury. 
Conversely various recent investigations had indicated 
that administration of  statins in high doses may itself 
directed to renal tubular cell injury (6). In a study on 
56 male Sprague Dawley rats, Reddy et al found that, 
high dose of  atorvastatin + garlic extract has negative 
safety profile when compared with groups having low 
dose of  statin and high dose of  garlic juice (8). They 
interpreted that, high dose of  atorvastatin induces 
damage to the kidney whether used either alone or 
in combination with high concentration of  garlic, 
whereas, low dose of  atorvastatin in combination 
with high concentration of  garlic juice has minimal 
nephrotoxic potential (8). Studies have shown, 
high-potency statins has been to be more effective 
in improving cardiovascular outcomes than use 
of  lower-potency statins. However, recent findings 
suggest that high-potency statin therapy may increase 
Table 1. Mean ± SD of  dilatation , degeneration, vacuolization and debris of  renal tubular cells
Groups Vacuolization Degeneration Debris Dilatation Score
Control: 0 10 ± 5 10.6 ± 5.5 2.31 ± 1.5 1.3 ± 0.7 4.2 ± 2.2
I: at 10 15 ± 12 15 ± 11 3.5  ± 1.6 2.3 ± 2.2 6.44 ± 4.9
II: at 50 34 ± 15 24.6 ± 15.7 18.3 ± 7.5 6.3 ± 9 15.4 ± 8.5
III: at 150 55 ± 25 50 ± 22.8 22.5 ± 13 9.5 ± 6 25.8 ± 12.7
Total 28.5 ± 23.6 25.08 ± 21 11.6 ± 11 4.8 ± 6.4 13 ± 11.5
F statistic 9.55 8.02 10.56 2.47 8.78
P value 0.0001 0.002 0.001 0.09 0.001
Table 2. Comparison of  dilatation, degeneration, vacuolization and debris of  renal tubular cells between groups
Between groups comparison Vacuolization Degeneration Dilatation Score
0 versus I 5 4.3 1.01 2.1
0 versus II 24.1 14 5.01 11.1
0 versus III 45* 39.3* 8.1 21.6*
I versus II 19.1 9.6 4 8.9
I versus III 40* 35* 7.1 19.4*
II versus III 20.8 25.3 3.1 10.4
*P values of  less than 0.01 were assumed to be significant (P < 0.01)
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the risk of  acute kidney injury (9). To compare the 
impact of  treatment with high-potency versus 
low-potency statins on risk of  acute kidney injury, 
Dormuth et al, analyzed the administrative healthcare 
records of  more than two million people aged ≥40 
years who received new prescriptions for statins 
during the investigation period (10). They detected 
that during the first 120 days of  therapy, patients 
without chronic renal failure who received high-
potency statins had a 34% higher risk of  acute kidney 
injury hospitalizations than those who received low-
potency statins. This risk remained increased for at 
least the first two years of  statin treatment. In patients 
with chronic renal failure, the use of  high-potency 
versus low-potency statins, did not significantly 
increase the risk of  hospitalization for acute kidney 
injury (10). They concluded that high-potency statin 
therapy may increase the risk of  rhabdomyolysis 
and proteinuria, suppress production of  the kidney 
protective antioxidant coenzyme Q10 and have other 
pleiotropic effects (10). These unintended adverse 
kidney effects was also indicated in previous studies. 
In a large scale, randomized controlled trial compared 
high dose (20 mg) rosuvastatin with placebo in almost 
18 000 patients. The results showed a non-significant 
increase of  19% in acute kidney injury (11). The non-
significant risk increased further to 35% when the 
endpoint also comprised doubling of  serum Cr. The 
non-significant risk increased further to 35% when the 
endpoint also comprised doubling of  serum Cr (11). 
Moreover, a population based investigation of  more 
than two million patients also detected that statin use 
was associated with a greater than 50% increase in 
risk of  acute kidney injury, with evidence of  raised 
risk within the first year of  statin administration, 
and a dose-response impact (12). A retrospective 
analysis of  statin use and hospital admission for acute 
kidney injury was conducted recently. The analysis 
is on large size, allows the detection of  differences 
in a relatively uncommon outcome which many 
randomized controlled trials are underpowered to 
find. Interestingly, the authors selected a high versus 
low-potency statin rather than statin versus no statin 
administration, confirming that all participants had 
an indication for statin treatment (13). Mechanisms 
of  renal toxicity by statins are ill-understood and 
potentially comprise of  interruption of  a wide 
variety of  metabolic functions including membrane 
glycoprotein composition and fluidity, chloride 
channel activation and impaired mitochondrial 
function by reduced ubiquinone synthesis that might 
render lipoproteins more vulnerable to oxidation 
injury. Renal injury associated with the use of  statins 
is frequently due to associated rhabdomyolysis 
producing acute tubular necrosis (14).
6. Conclusions
In the present study we found, atorvastatin with a 
doses of  150 mg/kg/day for 7 days was nephrotoxic 
for rats. While lower doses at 10 mg/kg/day or 50 
mg/kg/day for 7 days was not accompanied by renal 
injury. These findings imply further attention to the 
administration of  higher doses of  atorvastatin in 
clinical conditions.
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